FDA Grants Priority Review for Leqembi Iqlik Subcutaneous Dose
BioArctic AB’s partner Eisai announced that the U.S. Food and Drug Administration has granted Priority Review for the supplemental Biologics License Application for Leqembi Iqlik, a subcutaneous autoinjector designed...
